[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (1,380)

Search Parameters:
Keywords = laser therapy

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
13 pages, 1059 KiB  
Article
Multiple Sessions of Antimicrobial Photodynamic Therapy Improve Periodontal Outcomes in Patients with Down Syndrome: A 12-Month Randomized Clinical Trial
by Rafael Ferreira, Sebastião Luiz Aguiar Greghi, Adriana Campos Passanezi Sant’Ana, Mariana Schutzer Ragghianti Zangrando and Carla Andreotti Damante
Dent. J. 2025, 13(1), 33; https://doi.org/10.3390/dj13010033 (registering DOI) - 15 Jan 2025
Abstract
Background/Objectives: Individuals with Down syndrome (DS) often present with severe periodontal disease at a young age. Adjuvant treatments to scaling and root planing (SRP), such as antimicrobial photodynamic therapy (aPDT), may benefit this population. This study evaluated the effectiveness of aPDT as an [...] Read more.
Background/Objectives: Individuals with Down syndrome (DS) often present with severe periodontal disease at a young age. Adjuvant treatments to scaling and root planing (SRP), such as antimicrobial photodynamic therapy (aPDT), may benefit this population. This study evaluated the effectiveness of aPDT as an adjunct to SRP in individuals with DS. A randomized, double-blind, parallel trial was conducted with 37 individuals with DS. Methods: The test group (aPDT; n = 18) received SRP + aPDT, while the control group (C group; n = 19) received SRP only. For aPDT, a red laser (658 nm; 0.1 W; 2229 J/cm2; 40 s sweeping with optical fiber) combined with methylene blue (MB) (100 µg/mL) was applied across repeated sessions (on days 3, 7, and 14). Clinical parameters, such as plaque index (PI), clinical attachment level (CAL), probing depth (PD), and bleeding on probing (BOP), were recorded at baseline and after 3, 6, and 12 months of treatment. Statistical analyses were performed using parametric and non-parametric tests (p < 0.05). Results: Both treatments promoted improvements in all clinical periodontal parameters (p < 0.05). The aPDT group showed a statistically significant reduction in CAL at 3 months (aPDT = 4.58 mm vs. C = 4.72 mm; p < 0.05) and 12 months (aPDT = 4.59 mm vs. C = 4.84 mm; p < 0.05). Conclusions: aPDT improved periodontal health in the long term through a stable gain in attachment. Full article
(This article belongs to the Special Issue Laser Dentistry: The Current Status and Developments)
Show Figures

Figure 1

Figure 1
<p>Study design timeline.</p>
Full article ">Figure 2
<p>CONSORT flow diagram of the study showing randomization, allocation, and interventions. C—control group: scaling and root planing; aPDT—scaling and root planing + antimicrobial photodynamic therapy.</p>
Full article ">
26 pages, 3803 KiB  
Article
Novel Integration of Spatial and Single-Cell Omics Data Sets Enables Deeper Insights into IPF Pathogenesis
by Fei Wang, Liang Jin, Xue Wang, Baoliang Cui, Yingli Yang, Lori Duggan, Annette Schwartz Sterman, Sarah M. Lloyd, Lisa A. Hazelwood, Neha Chaudhary, Bhupinder Bawa, Lucy A. Phillips, Yupeng He and Yu Tian
Proteomes 2025, 13(1), 3; https://doi.org/10.3390/proteomes13010003 - 13 Jan 2025
Viewed by 232
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by repetitive alveolar injuries with excessive deposition of extracellular matrix (ECM) proteins. A crucial need in understanding IPF pathogenesis is identifying cell types associated with histopathological regions, particularly local fibrosis centers known as [...] Read more.
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by repetitive alveolar injuries with excessive deposition of extracellular matrix (ECM) proteins. A crucial need in understanding IPF pathogenesis is identifying cell types associated with histopathological regions, particularly local fibrosis centers known as fibroblast foci. To address this, we integrated published spatial transcriptomics and single-cell RNA sequencing (scRNA-seq) transcriptomics and adopted the Query method and the Overlap method to determine cell type enrichments in histopathological regions. Distinct fibroblast cell types are highly associated with fibroblast foci, and transitional alveolar type 2 and aberrant KRT5-/KRT17+ (KRT: keratin) epithelial cells are associated with morphologically normal alveoli in human IPF lungs. Furthermore, we employed laser capture microdissection-directed mass spectrometry to profile proteins. By comparing with another published similar dataset, common differentially expressed proteins and enriched pathways related to ECM structure organization and collagen processing were identified in fibroblast foci. Importantly, cell type enrichment results from innovative spatial proteomics and scRNA-seq data integration accord with those from spatial transcriptomics and scRNA-seq data integration, supporting the capability and versatility of the entire approach. In summary, we integrated spatial multi-omics with scRNA-seq data to identify disease-associated cell types and potential targets for novel therapies in IPF intervention. The approach can be further applied to other disease areas characterized by spatial heterogeneity. Full article
Show Figures

Figure 1

Figure 1
<p>Cell type enrichments in distinct region types integrating GeoMx spatial transcriptomics and scRNA-seq transcriptomics in human IPF lungs by the Query method. (<b>A</b>) Workflow of the Query method. In this example, differential analysis extracted up-regulated fibroblast foci-specific genes (n = 50) from GeoMx spatial transcriptomics [<a href="#B17-proteomes-13-00003" class="html-bibr">17</a>], and the sum expression of the whole gene set was queried as a z-score in PLIN2+ fibroblast cells from scRNA-seq transcriptomics [<a href="#B21-proteomes-13-00003" class="html-bibr">21</a>]. (<b>B</b>) PCA plotting of gene expression pattern. (<b>C</b>) Venn graph of the up-regulated region-specific gene sets in five histopathological region types: 32 up-regulated region-specific differential genes for control alveoli, 27 for IPF blood vessel, 41 for IPF distant alveoli, 50 for IPF fibroblast foci and 106 for IPF immune infiltrate. (<b>D</b>) Enrichment z-score summary of 30 cell types in five histopathological region types from spatial transcriptomics. These 30 cell types are classified into five large types: Epithelium, Mesenchyme, Myeloid, Endothelium and Lymphoid. Abbreviations. ACTA2: Smooth muscle alpha-actin; ADAM12: Disintegrin and metalloproteinase domain-containing protein 12; BMP5: Bone morphogenetic protein 5; VCAN: Versican; PC: principal component; AT1: Alveoli type 1 epithelial cells; AT2: Alveoli type 2 epithelial cells; KRT5: Keratin 5; KRT17: Keratin 17; MUC5AC: Mucin 5AC; MUC5B: Mucin 5B; SCGB3A2: secretoglobin family 3A member 2; SCGB3A1: secretoglobin family 3A member 1; PLIN2+: perilipin 2; cDCs: Conventional dendritic cells; pDCs: Plasmacytoid dendritic cells; NK cells: Natural killer cells. Cell type annotations from all figures follow the same abbreviations.</p>
Full article ">Figure 2
<p>Cell type enrichments in distinct region types integrating GeoMx spatial transcriptomics [<a href="#B17-proteomes-13-00003" class="html-bibr">17</a>] and scRNA-seq transcriptomics [<a href="#B21-proteomes-13-00003" class="html-bibr">21</a>] in human IPF lungs by the Overlap method. (<b>A</b>,<b>B</b>) Two representative workflow examples of the Overlap method. (<b>A</b>) Enrichment example: Differential analysis extracted up-regulated fibroblast foci-specific genes (n = 50) from GeoMx spatial transcriptomics and PLIN2+ fibroblast-specific genes (n = 576) from scRNA-seq transcriptomics and determined their overlap is larger than expected by random, indicative of enrichment. (<b>B</b>) Depletion example: Differential analysis extracted up-regulated fibroblast foci-specific genes (n = 50) from GeoMx spatial transcriptomics and mast cell-specific genes (n = 581) from scRNA-seq transcriptomics and determined their overlap is smaller than expected by random, indicative of depletion. (<b>C</b>) Enrichment <span class="html-italic">p</span>-value summary of 30 cell types in five histopathological region types from spatial transcriptomics. (<b>D</b>) Spearman’s correlations between cell type rankings in five histopathological defined region types from the Query method and the Overlap method. Abbreviations. ACTA2: Smooth muscle alpha-actin; ADAM12: Disintegrin and metalloproteinase domain-containing protein 12; BMP5: Bone morphogenetic protein 5; VCAN: Versican; ABCA9: ATP binding cassette subfamily A member 9; ABCF2: ATP binding cassette subfamily F member 2; ABL1: ABL proto-oncogene 1; ZNFX1: Zinc finger NFX1-type containing 1; ABCB8: ATP binding cassette subfamily B member 8; ABCC1: ATP binding cassette subfamily C member 1; ABCC4: ATP binding cassette subfamily C member 4; ZNRF1: Zinc and ring finger 1.</p>
Full article ">Figure 3
<p>Cell type enrichments in distinct region types integrating LCM-directed LC–MS spatial proteomics and scRNA-seq transcriptomics in human IPF lungs by the Query method and the Overlap method. (<b>A</b>) Enrichment z-score summary of 30 cell types in four histopathological region types from spatial proteomics. (<b>B</b>) Enrichment <span class="html-italic">p</span>-value summary of 30 cell types in four histopathological region types from spatial proteomics. (<b>C</b>) Spearman’s correlations between cell type rankings in four histopathological region types from the Query method and the Overlap method.</p>
Full article ">Figure 4
<p>Cell type enrichment comparisons by combining either GeoMx spatial transcriptomics or LCM-directed LC–MS spatial proteomics with scRNA-seq transcriptomics. (<b>A</b>) z-score comparisons by the Query method from spatial RNA/cellular RNA integration and spatial protein/cellular RNA integration in 30 cell types in three common region types: IPF fibroblast foci, IPF alveoli and control alveoli regions. (<b>B</b>) significance <span class="html-italic">p</span>-value comparisons by the Overlap method from spatial RNA/cellular RNA integration and spatial protein/cellular RNA integration in 30 cell types in three common region types: IPF fibroblast foci, IPF alveoli and control alveoli regions. Spearman’s correlations are calculated in each comparison.</p>
Full article ">
23 pages, 2707 KiB  
Review
The Evaluation, Diagnosis, and Management of Infantile Hemangiomas—A Comprehensive Review
by Arnes Rešić, Zoran Barčot, Dubravko Habek, Zenon Pogorelić and Marko Bašković
J. Clin. Med. 2025, 14(2), 425; https://doi.org/10.3390/jcm14020425 - 10 Jan 2025
Viewed by 413
Abstract
Infantile hemangioma (IH) is the most common pediatric benign vascular tumor. Its pathogenesis is still poorly understood, and it usually appears during the first few weeks of life and follows a characteristic natural course of proliferation and involution. Most IHs are small, benign, [...] Read more.
Infantile hemangioma (IH) is the most common pediatric benign vascular tumor. Its pathogenesis is still poorly understood, and it usually appears during the first few weeks of life and follows a characteristic natural course of proliferation and involution. Most IHs are small, benign, resolve spontaneously, and do not require active treatment but only active observation. A minority of IHs are potentially problematic because they can cause life-threatening complications, permanent disfigurement, and functional impairment. Diagnosis is usually clinical, and propranolol is currently the mainstay of treatment. Other therapeutic modalities may be used alone or in combination, depending on the characteristics of the specific IH. New treatment options are being explored every day, and some are showing promising results. It is undeniable that therapeutic modalities for IHs must be selected based on the child’s age, the size and location of the lesion, the presence of complications, the implementation conditions, and the possible outcomes of the treatment. The future of IH management will certainly be reflected in improved advanced imaging modalities, research into the genetic and molecular basis, the development of new pharmacological agents or techniques, and the development of standardized protocols, all to optimize outcomes with minimal side effects. Full article
(This article belongs to the Section Clinical Pediatrics)
Show Figures

Figure 1

Figure 1
<p>Classification of IHs according to depth: (<b>A</b>) superficial IH on chest; (<b>B</b>) deep IH on inner right thigh; (<b>C</b>) mixed IH at head; (<b>D</b>) IH-MAG on abdominal wall.</p>
Full article ">Figure 2
<p>Classification of IHs regarding pattern: (<b>A</b>) focal IH on back; (<b>B</b>) multifocal IHs; (<b>C</b>) segmental IH of frontotemporal region of head; (<b>D</b>) indeterminate hemangioma involving preauricular region within boundaries of mandibular segment.</p>
Full article ">Figure 3
<p>Multiple IHs within IHHs.</p>
Full article ">Figure 4
<p>Syndromes associated with segmental IHs: (<b>A</b>) large facial segmental IH associated with PHACE(S) syndrome; (<b>B</b>) large lumbosacral segmental IH associated with LUMBAR syndrome.</p>
Full article ">Figure 5
<p>Complications of IHs: (<b>A</b>) ulcerated IH on scalp; (<b>B</b>) bleeding IH of chest; (<b>C</b>) IH of lower lip, gums, and buccal mucosa; (<b>D</b>) periorbital IH.</p>
Full article ">Figure 6
<p>Therapy of IHs with oral propranolol: (<b>A</b>,<b>B</b>) therapy with propranolol 3 mg/kg/day for 8 months (before and after); (<b>C</b>,<b>D</b>) therapy with propranolol 2 mg/kg/day for 10 months (before and after).</p>
Full article ">Figure 7
<p>Topical therapy with 0.5% timolol maleate solution for 8 months: (<b>A</b>,<b>B</b>) dorsal side of index finger (before and after); (<b>C</b>,<b>D</b>) volar side of index finger (before and after).</p>
Full article ">Figure 8
<p>PHACE(S) syndrome: (<b>A</b>) residual IH after completion of propranolol therapy; (<b>B</b>) after PDL laser treatment.</p>
Full article ">Figure 9
<p>Mixed type of IH of upper leg: (<b>A</b>) clinical before excision; (<b>B</b>) excision of IH (5 × 3 cm).</p>
Full article ">
16 pages, 592 KiB  
Systematic Review
Treatment of Onychomycosis and the Drug–Drug Interactions in Patients with Diabetes Mellitus and Diabetic Foot Syndrome: A Systematic Review
by David Navarro-Pérez, Aroa Tardáguila-García, Sara García-Oreja, Francisco Javier Álvaro-Afonso, Mateo López-Moral and José Luis Lázaro-Martínez
Infect. Dis. Rep. 2025, 17(1), 4; https://doi.org/10.3390/idr17010004 - 9 Jan 2025
Viewed by 457
Abstract
Background: This systematic review reports on treatments for onychomycosis in patients with diabetes and the drug interactions with other drugs in regard to the complicated diabetic patient profile. Methods: The recommendations in the preferred reporting items for systematic reviews and meta-analysis (PRISMA) checklist [...] Read more.
Background: This systematic review reports on treatments for onychomycosis in patients with diabetes and the drug interactions with other drugs in regard to the complicated diabetic patient profile. Methods: The recommendations in the preferred reporting items for systematic reviews and meta-analysis (PRISMA) checklist were applied and the included studies were evaluated using the Consolidated Standards of Reporting Trials (CONSORT) statement and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Searches were conducted in November 2023, using the PubMed (Medline), Scopus, Cochrane Library, and Web of Science databases; studies on antifungal treatments for onychomycosis in patients with diabetes were included. Two authors performed the study selection and data extraction, and any discrepancies between the two reviewers were resolved through discussions with a third reviewer. This review was registered in PROSPERO (CRD42023442107). Results: The systematic review included 10 studies that met the selection criteria. Mycological cures for mild to moderate onychomycosis were: Ageratina pichinchensis (8.6%), 8% ciclopirox (8.6% 24 weeks and 54.3% 48 weeks), 10% efinaconazole (56.5–58.33%), terbinafine (73–76.6%), itraconazole (88.2%), and laser therapy (43.8%). No serious adverse effects or drug interactions were observed because patients with major complications, such as peripheral vascular disease, diabetic neuropathy, liver and renal dysfunction, poorly controlled diabetes, and severe onychomycosis, were excluded. Conclusions: The antifungal treatments described in the included studies are safe for patients with well-controlled diabetes, but there are currently no studies involving patients with diabetes and multiple complications, such as diabetic foot syndrome or severe onychomycosis. Thus, further research is needed in terms of this patient profile. Full article
Show Figures

Figure 1

Figure 1
<p>Flowchart for the identified studies.</p>
Full article ">
18 pages, 3612 KiB  
Article
810-nm Photobiomodulation Evokes Glutamate Release in Normal and Rotenone-Dysfunctional Cortical Nerve Terminals by Modulating Mitochondrial Energy Metabolism
by Silvia Ravera, Elisa Farsetti, Guido Maura, Manuela Marcoli, Matteo Bozzo, Chiara Cervetto and Andrea Amaroli
Cells 2025, 14(2), 67; https://doi.org/10.3390/cells14020067 - 7 Jan 2025
Viewed by 463
Abstract
The dysfunction of mitochondria, the primary source of cellular energy and producer of reactive oxygen species (ROS), is associated with brain aging and neurodegenerative diseases. Scientific evidence indicates that light in the visible and near-infrared spectrum can modulate mitochondrial activity, a phenomenon known [...] Read more.
The dysfunction of mitochondria, the primary source of cellular energy and producer of reactive oxygen species (ROS), is associated with brain aging and neurodegenerative diseases. Scientific evidence indicates that light in the visible and near-infrared spectrum can modulate mitochondrial activity, a phenomenon known in medicine as photobiomodulation therapy (PBM-t). The beneficial effects of PBM-t on dementia and neurodegeneration have been reviewed in the literature. However, the molecular mechanisms underlying these findings have yet to be fully elucidated. This study investigates the mechanism behind dose-dependent glutamate release in nerve terminals after irradiation with 810 nm, 1 W for 60 s continuous, 1 cm2, 1 W/cm2, 60 J, 60 J/cm2 (810 nm-1 W) or 810 nm, 0.1 W for 60 s continuous, 1 cm2, 0.1 W/cm2, 6 J, 6 J/cm2 (810 nm-0.1 W), focusing on mitochondrial activities. The results show that PBM modulated the mitochondrial metabolism of cortical nerve terminals and supported a power-dependent increase in oxidative phosphorylation (OxPhos) activity when stimulated with pyruvate plus malate (P/M) or succinate (succ) as respiratory substrates. The PBM-induced increase in OxPhos was sensitive to adding rotenone (Complex I inhibitor) and antimycin A (Complex III inhibitor) when synaptosomes were stimulated with P/M, but only to antimycin A when stimulated with succ. This allowed us to observe that the glutamate efflux, disrupted in the presence of rotenone, was partially restored by PBM due to the increase in the OxPhos pathway led by Complex II. This evidence suggests that PBM, acting on mitochondria, could facilitate physiological communication within the neuron-astrocyte network through vesicular glutamate release, potentially regulating healthy brain function and brain dysfunction. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Brief experimental setup description. A mouse model was used to obtain cortical nerve terminals (synaptosomes). After being collected in test tubes, they were irradiated with a diode laser at 810 nm with the parameters described in <a href="#sec2dot4-cells-14-00067" class="html-sec">Section 2.4</a>. The synaptosomes, key to our energy metabolism and oxidative stress experiments, were irradiated at the bottom of a glass cuvette. The synaptosomes were carefully placed on a filter at the bottom of a superfusion chamber for the glutamate release experiments. A power meter was meticulously used to ensure uniform irradiation under both experimental conditions. To assess the role of mitochondrial metabolism in PBM-evoked glutamate release, samples were treated with rotenone and antimycin, inhibitors of mitochondrial respiratory chain Complexes I and III, respectively. The effect of PBM on dysfunctional synaptosomes was tested using rotenone treatment.</p>
Full article ">Figure 2
<p>PBM effect on OxPhos activity of cortical synaptosomes. (<b>A</b>) Pyruvate plus malate (P/M)-induced ATP synthesis; (<b>B</b>) P/M-induced Oxygen Consumption Rate (OCR); (<b>C</b>) P/M-induced P/O value as an OxPhos efficiency marker; (<b>D</b>) Succinate (Succ)-induced ATP synthesis; (<b>E</b>) Succ-induced Oxygen Consumption Rate (OCR); (<b>F</b>) Succ-induced P/O value. All experiments were conducted in the absence (blue bars) or presence of 10 μM rotenone (red bars) or 10 μM antimycin A (green bars) to inhibit Complex I and Complex III, respectively. Data are represented as mean ± SEM and are presentative of four independent experiments. Significant differences were tested by one-way ANOVA followed by Tukey’s multiple comparisons test. **, ***, and **** indicate a <span class="html-italic">p</span> &lt; 0.01, <span class="html-italic">p</span> &lt; 0.001 or <span class="html-italic">p</span> &lt; 0.0001, ns indicates a non-statistically significant difference, respectively.</p>
Full article ">Figure 3
<p>Lipid peroxidation accumulation in cortical synaptosomes after PBM. The graph shows the intracellular MDA concentration as a lipid peroxidation marker. The experiments were conducted in the absence (blue bars) or presence of 10 μM rotenone (red bars) or 10 μM antimycin A (green bars) to inhibit Complex I and Complex III, respectively. Data are represented as mean ± SEM and are representative of four independent experiments. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test, and no significant differences were observed.</p>
Full article ">Figure 4
<p>Release of glutamate from cortical synaptosomes in the absence or the presence of rotenone: effects of photons in basal and physiological stimulation. Effects of photons (0.1 W, 60 s) on the basal release of glutamate in superfused cortical synaptosomes in the absence (white bar) or in the presence of rotenone (10 µM, white stripped bar). 4-AP (300 µM, 3 min–grey bar) -evoked glutamate overflow and effect of the co-application of photons (0.1W, 60 s–stripped grey bar). Effect of rotenone on the 4-AP (300 µM, 3 min–dark grey bar) -evoked glutamate overflow and counteracting impact of photons (0.1 W, 60 s–stripped dark grey bar). Bars represent the overflow of glutamate release, expressed as pmol/mg of protein, in the different experimental conditions reported in the legend. Photons were applied for 60 s in basal condition or during the 4-AP stimulation; rotenone was added 6 min before the stimulation and maintained till the end of the experiment. Further experimental details can be found in Materials and Methods. Data are expressed as mean ± SEM of n = 3 to 6 independent experiments. **** <span class="html-italic">p</span> &lt; 0.001 by one-way ANOVA followed by multiple comparisons test. ns indicates a non-statistically significant difference.</p>
Full article ">
19 pages, 328 KiB  
Review
The Diagnosis and Treatment of Branch Retinal Vein Occlusions: An Update
by Diana-Maria Darabuş, Rodica Georgiana Dărăbuş and Mihnea Munteanu
Biomedicines 2025, 13(1), 105; https://doi.org/10.3390/biomedicines13010105 - 5 Jan 2025
Viewed by 490
Abstract
Branch retinal vein occlusion (BRVO) is a common retinal vascular condition and a significant contributor to vision loss worldwide, particularly in middle-aged and elderly populations. This review synthesizes current knowledge on the epidemiology, pathogenesis, and clinical features of BRVO, alongside recent advancements in [...] Read more.
Branch retinal vein occlusion (BRVO) is a common retinal vascular condition and a significant contributor to vision loss worldwide, particularly in middle-aged and elderly populations. This review synthesizes current knowledge on the epidemiology, pathogenesis, and clinical features of BRVO, alongside recent advancements in diagnostic and therapeutic strategies. BRVO is approximately four times more prevalent than central retinal vein occlusion (CRVO) and often leads to significant vision impairment. By focusing on BRVO, this review aims to address the specific challenges and advancements in its diagnosis and management. The pathophysiology of BRVO is complex, involving factors such as venous compression, inflammation, and increased levels of vascular endothelial growth factor (VEGF). Diagnostic approaches such as optical coherence tomography (OCT) and fluorescein angiography are highlighted for their roles in assessing disease severity and guiding treatment decisions. Therapeutic interventions, including laser photocoagulation, anti-VEGF therapy, and intravitreal corticosteroids, are critically evaluated, emphasizing emerging treatments such as gene therapy, peptide-based agents, and small-molecule inhibitors. Despite advancements in management strategies, the recurrence of macular edema and treatment resistance remain significant challenges. Continued research is essential to refine therapeutic protocols and improve long-term visual outcomes for patients with BRVO. Full article
10 pages, 228 KiB  
Article
Assessing the Long-Term Effectiveness of Fractional CO2 Laser Treatment in Perimenopausal Women with Genitourinary Syndrome of Menopause—Single Center Preliminary Study
by Sławomir Woźniak and Andrzej Woźniak
J. Clin. Med. 2025, 14(1), 242; https://doi.org/10.3390/jcm14010242 - 3 Jan 2025
Viewed by 323
Abstract
Background: Genitourinary Syndrome of Menopause (GSM) is a prevalent condition in postmenopausal women characterized by symptoms such as vaginal dryness, itching, and urinary tract issues due to declining estrogen levels. Despite its widespread impact on quality of life, GSM often remains underdiagnosed and [...] Read more.
Background: Genitourinary Syndrome of Menopause (GSM) is a prevalent condition in postmenopausal women characterized by symptoms such as vaginal dryness, itching, and urinary tract issues due to declining estrogen levels. Despite its widespread impact on quality of life, GSM often remains underdiagnosed and without effective treatment. Methods: This study assessed the long-term efficacy of fractional CO2 laser treatment in alleviating GSM symptoms in perimenopausal women. The study involved 125 participants, with clinical evaluations conducted using vaginal pH, the Vaginal Health Index Score (VHIS), the Vaginal Maturation Index (VMI), and the Female Sexual Function Index (FSFI). Results: Results indicated significant improvements in these parameters, with pH levels decreasing, VHIS scores rising, and notable gains in VMI and FSFI observed up to 12 months post-treatment. This improvement has been validated through both subjective and objective assessments of GSM. Conclusions: The findings indicate that this method is effective and safe, with no significant side effects reported. However, conducting a long-term observational study on eventual longer protocol for maintaining the positive effect of this therapy should be conducted. Full article
(This article belongs to the Section Obstetrics & Gynecology)
13 pages, 2820 KiB  
Article
Polydopamine Coated Nonspherical Magnetic Nanocluster for Synergistic Dual Magneto-Photothermal Cancer Therapy
by Gracia García-García, Marina Lázaro, Pedro Urquiza, Tania Romacho, Ángel V. Delgado and Guillermo R. Iglesias
Polymers 2025, 17(1), 85; https://doi.org/10.3390/polym17010085 - 31 Dec 2024
Viewed by 539
Abstract
Local hyperthermia is gaining considerable interest due to its promising antitumor effects. In this context, dual magneto-photothermal cancer therapy holds great promise. For this purpose, the use of nanomaterials has been proposed. Therefore, the aim of this research is to develop a dual [...] Read more.
Local hyperthermia is gaining considerable interest due to its promising antitumor effects. In this context, dual magneto-photothermal cancer therapy holds great promise. For this purpose, the use of nanomaterials has been proposed. Therefore, the aim of this research is to develop a dual magneto-photothermal agent consisting of polydopamine-coated nonspherical magnetic nanoclusters. The physicochemical characterization of the nanoclusters was performed by electron microscopy, electron dispersive X-ray, dynamic light scattering, electrophoretic mobility, thermogravimetric analysis, and Fourier transform infrared spectroscopy. The biocompatibility of the nanoclusters was evaluated using human skin M1 fibroblasts. The potential of the nanoclusters as dual magneto-photothermal agents was investigated by applying an alternating magnetic field (18 kA/m and 165 kHz) and/or NIR laser (850 nm, 0.75 W/cm2). Nanoclusters showed a size of 350 nm consisting of nonspherical magnetic particles of 11 nm completely coated with polydopamine. In addition, they were superparamagnetic and did not significantly affect cell viability at concentrations below 200 µg/mL. Finally, the SAR values obtained for the nanoclusters demonstrated their suitability for magnetotherapy and phototherapy (71 and 41 W/g, respectively), with a synergistic effect when used together (176 W/g). Thus, this work has successfully developed polymeric-coated magnetic nanoclusters with the potential for dual magneto-photothermal cancer therapy. Full article
(This article belongs to the Special Issue Smart and Bio-Medical Polymers: 2nd Edition)
Show Figures

Figure 1

Figure 1
<p>(<b>a</b>) Scheme of the dual therapy with simultaneous application of a near-infrared (NIR) laser and an alternating magnetic field (AMF) to the polydopamine-coated magnetic nanoclusters (PDA-MNCs), (<b>b</b>) image of the sample irradiated with the laser inside the coil, and (<b>c</b>) image of the thermal imaging camera used for the dual therapy.</p>
Full article ">Figure 2
<p>(<b>a</b>,<b>b</b>) HRTEM and (<b>c</b>) particle size distribution of the MNPs.</p>
Full article ">Figure 3
<p>(<b>a</b>) High-resolution transmission electron microscopy (HRTEM), (<b>b</b>,<b>c</b>) high-angle annular dark field scanning transmission electron microscopy (HAADF-STEM), (<b>d</b>–<b>f</b>) energy dispersive X-ray (EDX) evaluation of the PDA-MNCs, and (<b>g</b>) EDX spectra and inserts of C,N and Fe element distributions. Bar length: 200 nm.</p>
Full article ">Figure 4
<p>FTIR analysis of the particles studied where the most significant peaks for comparison between MNP, PDA, and PDA-MNC have been identified in the highlighted regions (<b>a</b>–<b>d</b>).</p>
Full article ">Figure 5
<p>TGA spectra result for MNP, PDA, and PDA-MNC particles in terms of weight % and the obtained weight loss rate curve (mg/s). The most significant changes in the characterization of PDA-MNCs have been highlighted and identified as (<b>a</b>,<b>b</b>).</p>
Full article ">Figure 6
<p>Temperature increases (<b>a</b>,<b>b</b>) SAR values for PDA-MNC dispersion when applying MHT with 165 kHz and 18 kA/m (Red range), PTT with 850 nm and 0.75 W/cm<sup>2</sup> laser (blue range), and combined MHT and PTT (green range).</p>
Full article ">Figure 7
<p>Effects of PDA-MNCs on M1 human skin fibroblast viability. Cell proliferation was tested after 24 h exposure to PDA-MNCs (0–500 μg/mL). Data are shown as the mean ± SEM of at least three independent experiments and expressed as a percentage of untreated control levels. Cytotoxicity assays were performed in triplicates under experimental conditions. Statistical significance was established at <span class="html-italic">p</span> values below or equal to 0.05; ** <span class="html-italic">p</span> ≤ 0.01; *** <span class="html-italic">p</span> ≤ 0.001.</p>
Full article ">
14 pages, 4952 KiB  
Article
Efficacy of Photobiomodulation Therapy Utilizing 808 nm and 660 nm Alone and in Combination for Treatment of Paresthesia in Rats
by Ehsan Hajesmaelzade, Mohammad Mohammadi, Sina Kakooei, Luca Solimei, Stefano Benedicenti and Nasim Chiniforush
Biomedicines 2025, 13(1), 65; https://doi.org/10.3390/biomedicines13010065 - 30 Dec 2024
Viewed by 348
Abstract
Background/Objectives: This study assessed the efficacy of photobiomodulation therapy (PBM) by 808 nm and 660 nm alone and in combination for the treatment of paresthesia in rats. Methods: This animal study was conducted on 36 adult male Wistar rats. After general [...] Read more.
Background/Objectives: This study assessed the efficacy of photobiomodulation therapy (PBM) by 808 nm and 660 nm alone and in combination for the treatment of paresthesia in rats. Methods: This animal study was conducted on 36 adult male Wistar rats. After general anesthesia, the facial nerve of the right side of the face of rats was surgically exposed and pinched, returned in place, and sutured. The rats were randomly assigned to six groups (n = 6) of (I) no-intervention (control), (II) no-laser, (III) 808 nm laser (250 mW, 4 W/cm2, 20 s, 8 J/cm2, (IV) 660 nm laser (150 mW, 0.25 W/cm2, 32 s, 8 J/cm2, (V) 808 nm plus 660 nm laser with the original settings, and (VI) 808 nm plus 660 nm laser with half of the time and energy density. After 16 days, a biopsy sample was taken from the nerve injury site and underwent histological, histometric, and immunohistochemical assessments. Results: Significantly lower edema and congestion were seen in the combined laser group with original settings (p < 0.05); this group had no significant difference with the control group regarding degenerative changes of the nerve fibers and Schwann cells (p > 0.05). The 660 nm, and combined laser groups, had a significantly lower accumulation of inflammatory cells (p < 0.05). The number of blood vessels in combined laser groups was significantly lower than that in the no-laser group (p < 0.05). Conclusions: The results showed the positive efficacy of PBM by 808 nm and 660 nm lasers in resolution of inflammation and reduction of degenerative changes of Schwann cells and nerve fibers. Full article
(This article belongs to the Section Neurobiology and Clinical Neuroscience)
Show Figures

Figure 1

Figure 1
<p>Histological micrographs of the control group; (<b>A</b>–<b>C</b>) H and E staining with ×10, ×20, and ×40 magnification, respectively; (<b>D</b>–<b>F</b>) S100 staining with ×10, ×20, and ×40 magnification, respectively.</p>
Full article ">Figure 2
<p>Histological micrographs of the no-laser group; (<b>A</b>–<b>C</b>) H and E staining with ×10, ×20, and ×40 magnification, respectively; (<b>D</b>–<b>F</b>) S100 staining with ×10, ×20, and ×40 magnification, respectively.</p>
Full article ">Figure 3
<p>Histological micrographs of 808 nm laser group with 20 s irradiation time and 8 J/cm<sup>2</sup> energy density; (<b>A</b>–<b>C</b>) H and E staining with ×10, ×20, and ×40 magnification, respectively; (<b>D</b>–<b>F</b>) S100 staining with ×10, ×20, and ×40 magnification, respectively.</p>
Full article ">Figure 4
<p>Histological micrographs of the 660 nm laser group with 20 s irradiation time and 8 J/cm<sup>2</sup> energy density; (<b>A</b>–<b>C</b>) H and E staining with ×10, ×20, and ×40 magnification, respectively; (<b>D</b>–<b>F</b>) S100 staining with ×10, ×20, and ×40 magnification, respectively.</p>
Full article ">Figure 5
<p>Histological micrographs of 808 nm and 660 nm combined laser group with half the time (10 s) and energy density (4 J/cm<sup>2</sup>); (<b>A</b>–<b>C</b>) H and E staining with ×10, ×20, and ×40 magnification, respectively; (<b>D</b>–<b>F</b>) S100 staining with ×10, ×20, and ×40 magnification, respectively.</p>
Full article ">Figure 6
<p>Histological micrographs of 808 nm and 660 nm combined laser group with original time (20 s) and energy density (8 J/cm<sup>2</sup>); (<b>A</b>–<b>C</b>) H and E staining with ×10, ×20, and ×40 magnification, respectively; (<b>D</b>–<b>F</b>) S100 staining with ×10, ×20, and ×40 magnification, respectively.</p>
Full article ">
14 pages, 5115 KiB  
Article
Open Partial Horizontal Laryngectomy as a Conservative Salvage Treatment for Laser-Recurrent Laryngeal Cancer: A Multi-Institutional Series
by Erika Crosetti, Andrea Borello, Andy Bertolin, Izabela Costa Santos, Marco Fantini, Giulia Arrigoni, Ilaria Bertotto, Andrea Elio Sprio, Fernando Luiz Dias, Giuseppe Rizzotto and Giovanni Succo
Curr. Oncol. 2025, 32(1), 12; https://doi.org/10.3390/curroncol32010012 - 27 Dec 2024
Viewed by 448
Abstract
Early-stage laryngeal cancer (T1-T2) is commonly treated with organ-preserving techniques such as transoral laser microsurgery (TOLMS) or radiation therapy (RT), both providing comparable oncological outcomes but differing in functional results. Local recurrence occurs in approximately 10% of cases, making salvage surgery a crucial [...] Read more.
Early-stage laryngeal cancer (T1-T2) is commonly treated with organ-preserving techniques such as transoral laser microsurgery (TOLMS) or radiation therapy (RT), both providing comparable oncological outcomes but differing in functional results. Local recurrence occurs in approximately 10% of cases, making salvage surgery a crucial therapeutic option. This multi-institutional study investigates the efficacy of open partial horizontal laryngectomy (OPHL) as a salvage treatment, following recurrent laryngeal squamous-cell carcinoma (LSCC) after failed TOLMS. This analysis includes 66 patients who underwent OPHL between 1995 and 2017, reporting favorable oncological outcomes with overall survival (OS) of 87.4%, disease-specific survival (DSS) of 93.4%, and disease-free survival (DFS) of 85.5%. A recurrence rate of 10.6% was observed post-salvage OPHL, with vascular invasion and advanced pathological staging identified as significant predictors of recurrence. OPHL emerged as an effective organ-preserving alternative to total laryngectomy (TL) in select patients, especially those with limited tumor spread and preserved laryngeal function. The study highlights the importance of careful patient selection and thorough preoperative assessment to improve outcomes, positioning OPHL as a key option in treating recurrent laryngeal cancer and offering oncological control while preserving laryngeal functions. Full article
Show Figures

Figure 1

Figure 1
<p>Recurrent right glottic SCC after TOLM: MR sequences FSE T2-weighted on the axial plane (<b>A</b>) and FSE T1-weighted after contrast injection on the coronal plane (<b>B</b>). An irregular thickening (arrows) of the right side of the glottic level is suspicious for tumor. Oedematous changes are present (asterisk) (<b>A</b>). The lesion does not involve the subglottic region (<b>B</b>). Axial scheme of resection (Type IIa OPHL + right ARY) (<b>C</b>) [<a href="#B10-curroncol-32-00012" class="html-bibr">10</a>].</p>
Full article ">Figure 2
<p>Recurrent glottic SCC after TOLM. Contrast-enhanced CT scan shows neoplastic tissue (t) in the anterior and left sides of glottic level. The lysis (arrows) of the thyroid cartilage is indicative of tumoral invasion at full thickness (<b>A</b>). On the coronal reconstruction, the lesion presents transglottic spread; there is no certain tumoral extension into the subglottic region (<b>B</b>). Sagittal scheme of resection (Type IIIa OPHL) (<b>C</b>) [<a href="#B10-curroncol-32-00012" class="html-bibr">10</a>].</p>
Full article ">Figure 3
<p>Distribution of patients according to the clinical (rcT) and pathological (rpT) classification of recurrent disease.</p>
Full article ">Figure 4
<p>Overall survival (OS) according to the laryngeal compartmentalization, need for adjuvant treatments and type of surgery # = <span class="html-italic">p</span> &lt; 0.05 (GBW).</p>
Full article ">Figure 5
<p>Disease-free survival (DFS) according to the laryngeal compartmentalization, need for adjuvant treatments and type of surgery * = <span class="html-italic">p</span> &lt; 0.05, ** = <span class="html-italic">p</span> &lt; 0.01 (LR); ## = <span class="html-italic">p</span> &lt; 0.01 (GBW).</p>
Full article ">Figure 6
<p>Disease-specific survival (DSS) according to the laryngeal compartmentalization, need for adjuvant treatments and type of surgery.</p>
Full article ">Figure 7
<p>Freedom from laryngectomy (FFL) according to the laryngeal compartmentalization, need for adjuvant treatments and type of surgery.</p>
Full article ">Figure 8
<p>Laryngo–esophageal dysfunction-free survival (LEDFS) according to the laryngeal compartmentalization, need for adjuvant treatments and type of surgery * = <span class="html-italic">p</span> &lt; 0.05, ** = <span class="html-italic">p</span> &lt; 0.01 (LR); ## = <span class="html-italic">p</span> &lt; 0.01 (GBW).</p>
Full article ">
21 pages, 3723 KiB  
Review
Advances in Deep Brain Imaging with Quantum Dots: Structural, Functional, and Disease-Specific Roles
by Tenesha Connor, Hemal Weerasinghe, Justin Lathia, Clemens Burda and Murat Yildirim
Photonics 2025, 12(1), 3; https://doi.org/10.3390/photonics12010003 - 24 Dec 2024
Viewed by 966
Abstract
Quantum dots (QDs) have emerged as promising tools in advancing multiphoton microscopy (MPM) for deep brain imaging, addressing long-standing challenges in resolution, penetration depth, and light–tissue interactions. MPM, which relies on nonlinear photon absorption, enables fluorescence imaging within defined volumes, effectively reducing background [...] Read more.
Quantum dots (QDs) have emerged as promising tools in advancing multiphoton microscopy (MPM) for deep brain imaging, addressing long-standing challenges in resolution, penetration depth, and light–tissue interactions. MPM, which relies on nonlinear photon absorption, enables fluorescence imaging within defined volumes, effectively reducing background noise and photobleaching. However, achieving greater depths remains limited by light scattering and absorption, compounded by the need for balanced laser power to avoid tissue damage. QDs, nanoscale semiconductor particles with unique optical properties, offer substantial advantages over traditional fluorophores, including high quantum yields, large absorption cross-sections, superior photostability, and tunable emission spectra. These properties enhance signal to background ratio at increased depths and reduce scattering effects, making QDs ideal for imaging subcortical regions like the hippocampus without extensive microscope modifications. Studies have demonstrated the capability of QDs to achieve imaging depths up to 2100 μm, far exceeding that of conventional fluorophores. Beyond structural imaging, QDs facilitate functional imaging applications, such as high-resolution tracking of hemodynamic responses and neural activity, supporting investigations of neuronal dynamics and blood flow in vivo. Their stability enables long-term, targeted drug delivery and photodynamic therapy, presenting potential therapeutic applications in treating brain tumors, Alzheimer’s disease, and traumatic brain injury. This review highlights the impact of QDs on MPM, their effectiveness in overcoming light attenuation in deep tissue, and their expanding role in diagnosing and treating neurological disorders, positioning them as transformative agents for both brain imaging and intervention. Full article
(This article belongs to the Special Issue Emerging Trends in Multi-photon Microscopy)
Show Figures

Figure 1

Figure 1
<p>Optical properties of various fluorophores used in deep brain imaging. (<b>A</b>) Comparison of absorption crosssection (η<span class="html-italic">σ<sub>3</sub></span>) for commercial QDs (Qtracker) and traditional dyes (Texas Red and SR101) across wavelength 1600 to 1840 nm. Adapted from [<a href="#B25-photonics-12-00003" class="html-bibr">25</a>]. (<b>B</b>) η<span class="html-italic">σ<sub>3</sub></span> for lab-created CdTe QDs, showing increased values with additional shell layers (CdSe, CdSe/ZnS) under 1600 nm excitation. Adapted from [<a href="#B36-photonics-12-00003" class="html-bibr">36</a>]. (<b>C</b>) Fluorescence decay comparison between common fluorophores and CdSe/ZnS QDs. Cy5 and Nile Red exhibit mono-exponential decays with lifetimes of 1.5 ns and 3.6 ns, respectively, while QD displays multi-exponential decay with mean lifetime of 10.3 ns, demonstrating significantly longer fluorescence duration. Adapted from [<a href="#B34-photonics-12-00003" class="html-bibr">34</a>].</p>
Full article ">Figure 2
<p>Structural multiphoton imaging (in vivo) of mouse brain vasculature at various depths using quantum dots (QDs) as fluorescent probe. (<b>A</b>) Images acquired at depths measured up to ~500 µm below dura-mater utilizing 2P modified microscopy systems comparing 800 nm NLO or 1050 nm OPO excitation in healthy mice intravenously injected with Qtracker655. Adapted from [<a href="#B44-photonics-12-00003" class="html-bibr">44</a>]. (<b>B</b>) Three-dimensional reconstruction of 3P imaging of vasculature labeled in red with Qtracker655 illustrating depths deep into the hippocampus (~2100 μm) obtained. Highlighted in green are third-harmonic generation (THG) signals outlining the white matter (860–100 μm below surface). Adapted from [<a href="#B25-photonics-12-00003" class="html-bibr">25</a>]. (<b>C</b>) The yellow color highlights mouse brain blood vessels labeled by QDs excited at 2200 nm. The cyan color shows THG imaging of white matter excited at 1700 nm. (<b>Left</b>): Three-dimensional reconstruction of 3P imaging of mouse vasculature labeled with Qtracker800 extending to ~1060 μm below surface. (<b>Right</b>): Three-dimensional reconstruction of 4P imaging of Qtracker655-labeled mouse vasculature extending to ~940 μm below surface. Adapted from [<a href="#B24-photonics-12-00003" class="html-bibr">24</a>]. (<b>D</b>) Schematic showing 3P imaging of PEGylated CdSe/5.8Cd/ZnS QD-labeled vasculature excited with 1600 nm in healthy mouse brain. Left: Schematic of mouse injected with QDs into the tail before brain imaging a craniotomy. A 3D reconstruction of the blood vessels shows imaging acquired without the skull achieved depths ~1550 μm. Fluorescence intensity and SBR measurements were also obtained at 1300 nm (SBR = 2.7) and 1550 nm (SBR = 1.7) imaging depths as shown in the two graphs below the schematic. Right: Schematic showing 3P imaging acquired through intact skull. Lower imagining depth is achieved though the skull (~850 μm). A 3D reconstruction of the vasculature is presented in the far right. Fluorescence intensity and SBR measurement were obtained at 850 μm (SBR = 2.3). Adapted from [<a href="#B26-photonics-12-00003" class="html-bibr">26</a>].</p>
Full article ">Figure 3
<p>QDs in various functional imaging applications in the brain. (<b>A</b>) In vivo 3PFM images of Qtracker655-labeled blood vessels at (<b>a</b>) 950 μm, (<b>c</b>) 1330 μm, (<b>e</b>) and 1660 μm below the brain surface. Green signal in (<b>a</b>) Shows myelinated axons. Line scans (<b>b</b>,<b>d</b>,<b>f</b>) along dashed lines measure blood flow speed. Pixel: 512 × 512. Adapted from [<a href="#B24-photonics-12-00003" class="html-bibr">24</a>]. (<b>B</b>) Simulated ΔF/F changes for cortical spike trans using QDs, VSDs, and GEVIs, assuming 105 indicators per ell with 100% membrane localization. Sampled at 10 kHz with excitation intensities of 100 mW/mm<sup>2</sup>. Adapted from [<a href="#B56-photonics-12-00003" class="html-bibr">56</a>]. (<b>C</b>) In vivo imaging of cortical stimulation with QD-JB1-C60 bioconjugates. (<b>Left</b>) Fluorescence at 575 ms shows four ROIs (A1–A4), with electrode position marked by white lines. (<b>Right</b>) ΔF/F% intensity profiles for ROI A1 across three mice, showing peak response (~2.1%) ~100 ms post-stimulation and return to baseline within 80–100 ms. Adapted from [<a href="#B50-photonics-12-00003" class="html-bibr">50</a>]. (<b>D</b>) Fluorescence images of neurons co-labeled with CdSe/ZnS-GSH QDs (green) and DiD (red), with merged images showing colocalization (yellow). DiD, a lipophilic dye embedded in the phospholipid bilayer, highlights cell membranes. The overlap of the images confirms the QDs correctly labeled the cell membranes of neurons. Adapted from [<a href="#B58-photonics-12-00003" class="html-bibr">58</a>]. (<b>E</b>) Flexible QD biointerfaces for photomodulation of neurons using NIR light. NIR light stimulates neurons in primary hippocampal neurons in vitro to generate safe capacitive ionic currents that generate action potentials. Adapted from [<a href="#B55-photonics-12-00003" class="html-bibr">55</a>].</p>
Full article ">Figure 4
<p>Schematic representations of synthesis methods and modifications utilized to create QDs for deep brain imaging and neuron tracking. (<b>A</b>) Depiction of four NIR QD synthesis methods, including (i) hot injection: sequential precursor addition at high temperature, (ii) heat up: gradual temperature increase after mixing all precursors, (iii) microwave: rapid heating via microwave for core growth, and (iv) hydrothermal: high-pressure, high-temperature growth in an autoclave. Adapted from [<a href="#B61-photonics-12-00003" class="html-bibr">61</a>]. (<b>B</b>) Depiction of band-gap engineering strategies to create specific band structure alignments in Cd/CdSe/ZnS QDs with a type II configuration, resulting in enhanced 3P fluorescence efficiency. Adapted from [<a href="#B36-photonics-12-00003" class="html-bibr">36</a>]. (<b>C</b>) Representation of a modular design for a targeted approach for QD-based bioconjugates to enhance membrane potential visualization with varying electron acceptor distances. Adapted from [<a href="#B50-photonics-12-00003" class="html-bibr">50</a>]. (<b>D</b>) Schematic illustration of various bioconjugation techniques: (<b>left</b>) biomolecules of interest and (<b>right</b>) surface coating approaches for QDs. Two main coating methods: amphiphilic polymer encapsulation (i,ii) and cap exchange with hydrophilic ligands (iii–v). Adapted from [<a href="#B75-photonics-12-00003" class="html-bibr">75</a>].</p>
Full article ">Figure 5
<p>Utilizing QDs for neurological applications in pathologies and disease. (<b>A</b>) Schematic illustration of the use of QDs for targeting imaging and therapy of brain tumors. QDs selectively accumulate in tumor cells, enabling their specific visualization with MPM, which can then be used therapeutically to induce targeted cell death. Designed using Biorender. (<b>B</b>) In vivo glioma imaging in rats 8 h post-injection with PEG-QDs (<b>left</b>) and NGR-PEG-QDs (<b>right</b>). Fluorescence is negligible with PEG-QDs but pronounced at the tumor site with NGR-PEG-QDs, enhancing glioma detection. Adapted from [<a href="#B91-photonics-12-00003" class="html-bibr">91</a>]. (<b>C</b>) Schematic of GQD-GPE treatment in APP/PS1 mice, targeting Aβ accumulation and neuroinflammation. GQDG administration led to Aβ clearance, reduced inflammation, and improved memory. Adapted from [<a href="#B97-photonics-12-00003" class="html-bibr">97</a>,<a href="#B98-photonics-12-00003" class="html-bibr">98</a>]. (<b>D</b>) Schematic representation of biofunctionalized QDs delivering drugs across the BBB via receptor-mediated transcytosis, targeting brain cancer cells. Once inside, QDs bind specific receptors (e.g., EGFR, VEGFR, folate) to release drugs and induce cytotoxicity. Adapted from [<a href="#B93-photonics-12-00003" class="html-bibr">93</a>].</p>
Full article ">
14 pages, 3487 KiB  
Article
Femtosecond Laser-Induced Photothermal Effects of Ultrasmall Plasmonic Gold Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells
by Poornima Budime Santhosh, Kamelia Hristova-Panusheva, Todor Petrov, Lyubomir Stoychev, Natalia Krasteva and Julia Genova
Cells 2024, 13(24), 2139; https://doi.org/10.3390/cells13242139 - 23 Dec 2024
Viewed by 399
Abstract
Laser-induced photothermal therapy using gold nanoparticles (AuNPs) has emerged as a promising approach to cancer therapy. However, optimizing various laser parameters is critical for enhancing the photothermal conversion efficacy of plasmonic nanomaterials. In this regard, the present study investigates the photothermal effects of [...] Read more.
Laser-induced photothermal therapy using gold nanoparticles (AuNPs) has emerged as a promising approach to cancer therapy. However, optimizing various laser parameters is critical for enhancing the photothermal conversion efficacy of plasmonic nanomaterials. In this regard, the present study investigates the photothermal effects of dodecanethiol-stabilized hydrophobic ultrasmall spherical AuNPs (TEM size 2.2 ± 1.1 nm), induced by a 343 nm wavelength ultrafast femtosecond-pulse laser with a low intensity (0.1 W/cm2) for 5 and 10 min, on the cell morphology and viability of human hepatocellular carcinoma (HepG2) cells treated in vitro. The optical microscopy images showed considerable alteration in the overall morphology of the cells treated with AuNPs and irradiated with laser light. Infrared thermometer measurements showed that the temperature of the cell medium treated with AuNPs and exposed to the laser increased steadily from 22 °C to 46 °C and 48.5 °C after 5 and 10 min, respectively. The WST-1 assay results showed a significant reduction in cell viability, demonstrating a synergistic therapeutic effect of the femtosecond laser and AuNPs on HepG2 cells. The obtained results pave the way to design a less expensive, effective, and minimally invasive photothermal approach to treat cancers with reduced side effects. Full article
Show Figures

Figure 1

Figure 1
<p>(<b>a</b>) TEM image of dodecanethiol-stabilized hydrophobic AuNPs; (<b>b</b>) DLS measurements showing the hydrodynamic diameter of AuNPs.</p>
Full article ">Figure 2
<p>Experimental setup of the femtosecond laser system: (<b>a</b>) photo and (<b>b</b>) schematics.</p>
Full article ">Figure 3
<p>Temperature increase induced by pulsed fs laser in wells containing cells with or without AuNPs at various time intervals.</p>
Full article ">Figure 4
<p>WST-1 assay result depicting the HepG2 cell viability (%) of control cells, cells treated with AuNPs alone, and cells treated with AuNPs and irradiated with a 343 nm pulsed laser with 0.1 W/cm<sup>2</sup> power density at different time intervals.</p>
Full article ">Figure 5
<p>Overall morphology of HepG2 cells following irradiation at a 343 nm wavelength, with and without AuNP treatment: (<b>a</b>) Control cells (untreated, non-irradiated). (<b>b</b>) Cells irradiated at 0.1 W/cm<sup>2</sup> power density for 5 min without AuNPs. (<b>c</b>) Cells irradiated for 10 min without AuNPs. (<b>d</b>) Cells treated with AuNPs but not irradiated. (<b>e</b>) Cells treated with AuNPs and irradiated with a 343 nm laser at 0.1 W/cm<sup>2</sup> power density for 5 min. (<b>f</b>) Cells treated with AuNPs and irradiated under the same conditions for 10 min. Scale bar: 100 µm.</p>
Full article ">
11 pages, 8503 KiB  
Article
Dye Laser Applications in Cosmetic Dermatology: Efficacy and Safety in Treating Vascular Lesions and Scars
by Alessandro Clementi, Giovanni Cannarozzo, Simone Amato, Elena Zappia, Luigi Bennardo, Simone Michelini, Cristiano Morini, Mario Sannino, Caterina Longo and Steven Paul Nistico
Cosmetics 2024, 11(6), 227; https://doi.org/10.3390/cosmetics11060227 - 23 Dec 2024
Viewed by 593
Abstract
Cosmetic dermatology increasingly utilizes laser technologies to address various aesthetic concerns. This study evaluates the efficacy of the flash-lamp pulsed-dye laser (FPDL) in treating vascular and scar-related conditions. A cohort of 71 patients with diverse vascular lesions, including facial telangiectasia, port-wine stains (PWSs), [...] Read more.
Cosmetic dermatology increasingly utilizes laser technologies to address various aesthetic concerns. This study evaluates the efficacy of the flash-lamp pulsed-dye laser (FPDL) in treating vascular and scar-related conditions. A cohort of 71 patients with diverse vascular lesions, including facial telangiectasia, port-wine stains (PWSs), striae rubrae, erythematous acne scars, facial traumatic scars, and keloids, was treated using the FPDL (Synchro Vas-Q, Deka MELA). Treatment protocols varied based on lesion type, with sessions ranging from one to eight at intervals of four to eight weeks. Clinical outcomes were assessed using a four-point grading scale and patient satisfaction surveys. Results indicated that 70.4% of patients achieved excellent clearance of lesions, while 16.9% and 9.9% showed moderate-good and slight clearance, respectively. Minimal or no improvement was observed in 2.8% of cases. High patient satisfaction was reported, correlating with effective lesion reduction and manageable side effects, primarily post-operative purpura. The study underscores FPDL’s selective efficacy for hemoglobin-rich lesions and its safety profile, advocating for its continued use in cosmetic dermatological practices. These findings contribute to the growing evidence supporting laser therapy as a pivotal tool in aesthetic medicine, emphasizing the importance of tailored treatment protocols and patient education for optimal outcomes. Full article
Show Figures

Figure 1

Figure 1
<p>(<b>a</b>) A young woman affected by rosacea at baseline; (<b>b</b>) Outstanding results observed after two PDL sessions.</p>
Full article ">Figure 2
<p>(<b>a</b>) Baseline appearance of a patient with a keloid on the nasolabial fold; (<b>b</b>) Typical post-PDL purpura; (<b>c</b>) Impressive improvement following four sessions of PDL therapy.</p>
Full article ">Figure 3
<p>(<b>a</b>) Striae rubrae in a female patient prior to treatment; (<b>b</b>) Typical post-PDL purpura; (<b>c</b>) Marked clinical improvement with four PDL sessions.</p>
Full article ">Figure 4
<p>(<b>a</b>) A PWS on the nasolabial fold at baseline; (<b>b</b>) Purpura reaction post-PDL session; (<b>c</b>) Significant improvement observed 8 weeks following the last PDL session.</p>
Full article ">Figure 5
<p>(<b>a</b>) A traumatic scar located in the pre-jowl area; (<b>b</b>) Immediate purpura following PDL therapy; (<b>c</b>) Disappearance of the lesion after three sessions of PDL therapy; (<b>d</b>) Treatment included the oral mucosa due to the presence of scar tissue in that area; (<b>e</b>) Typical post-PDL purpura.</p>
Full article ">Figure 6
<p>(<b>a</b>) Erythematous acne scars on the right cheek of a young patient before treatment; (<b>b</b>) Post-PDL treatment purpura; (<b>c</b>) Substantial reduction of scars after three PDL sessions.</p>
Full article ">Figure 7
<p>(<b>a</b>) Subpalpebral telangiectasias at baseline; (<b>b</b>) Significant improvement following a single PDL session.</p>
Full article ">
14 pages, 1633 KiB  
Article
Impact of Postoperative Norepinephrine Administration on Free Flap Flow
by Denis Ehrl, Svenja Pistek, Clemens Rieder, Michael Irlbeck, Klaus Hofmann-Kiefer, David Braig, Frederic Klein, Philipp Groene, Riccardo E. Giunta and Nicholas Moellhoff
J. Clin. Med. 2024, 13(24), 7816; https://doi.org/10.3390/jcm13247816 - 20 Dec 2024
Viewed by 427
Abstract
Background/Objectives: The perioperative interplay between blood pressure, vasopressors, and macrocirculation is well established. However, in the context of free flap surgery, the potential impact of these factors on microvascular flow remains elusive. The aim was to evaluate the impact of norepinephrine administration on [...] Read more.
Background/Objectives: The perioperative interplay between blood pressure, vasopressors, and macrocirculation is well established. However, in the context of free flap surgery, the potential impact of these factors on microvascular flow remains elusive. The aim was to evaluate the impact of norepinephrine administration on the microcirculation of free flaps. Methods: Postoperative systolic blood pressure (sBP), norepinephrine infusion rates (NIRs), and free flap microcirculation were monitored prospectively and analyzed retrospectively in patients receiving free flap surgery who required postoperative intermediate (IMC) or intensive care (ICU). Blood flow, hemoglobin oxygenation (SO2), and relative hemoglobin levels (rHbs) were measured over a period of 24 hours post-anastomosis by laser-doppler flowmetry and white light spectroscopy using the “Oxygen to See” device (O2C, LEA Medizintechnik, Gießen, Germany). Multivariate analysis was performed to determine the impact of NIR on microvascular flow, adjusting for several confounding factors. Subgroup analysis was conducted by categorizing into three groups based on patients’ postoperative sBP. Results: Flaps were performed in 105 patients with a mean age of 61.46 ± 16.29 years. Postoperatively, an increase in microvascular flow over time was observed across all free flaps, while NIR decreased and sBP maintained stable values. Multivariate analysis revealed that the time post-anastomosis (B = 3.76, p < 0.001), SO2 (B = 0.55, p < 0.001), rHb (B= −0.79, p < 0.001), female gender (B = 29.25, p = 0.02), and no previous radiation therapy (B = 41.21, p = 0.04) had a significant impact on postoperative microvascular flow in free flaps. NIR, sBP, smoking status, old age, and ASA score showed no significant impact on free flap flow. Further, NIR showed no significant impact on microvascular flow in any of the subgroups investigated. Conclusions: These findings support the safety of using norepinephrine for maintaining stable blood pressure without compromising microvascular flow, offering valuable guidance for postoperative management. Full article
(This article belongs to the Special Issue Clinical Advances in Plastic Surgery)
Show Figures

Figure 1

Figure 1
<p>Development of microvascular flow, systolic blood pressure, and norepinephrine infusion rate over 24 h post-anastomosis.</p>
Full article ">Figure 2
<p>Microvascular flow quantiles over time.</p>
Full article ">Figure 3
<p>Development of microvascular flow in irradiated vs. non-irradiated patients over 24 h post-anastomosis.</p>
Full article ">Figure 4
<p>Subgroup analysis according to initial blood pressure values (low sBP, intermediate sBP, high sBP) of the development of norepinephrine infusion rates (<b>A</b>), microvascular flow (<b>B</b>), and systolic blood pressure (<b>C</b>).</p>
Full article ">
11 pages, 894 KiB  
Article
The Effect of Intravascular Laser Irradiation of Blood on Serum Biomarkers and Clinical Outcome in Knee Osteoarthritis Patients: A Double-Blind Randomized Control Trial
by Yu-Chi Su, Yu-Ping Shen, Chih-Ya Chang, Ke-Ting Pan, Shih-Ming Huang and Liang-Cheng Chen
Int. J. Mol. Sci. 2024, 25(24), 13608; https://doi.org/10.3390/ijms252413608 - 19 Dec 2024
Viewed by 460
Abstract
Knee osteoarthritis (OA) is a prevalent degenerative joint disease globally, causing pain, stiffness, and disability. Intravascular laser irradiation of blood (ILIB) has been used for chronic pain and musculoskeletal disease. However, evidence on the clinical benefits and serum biomarkers post-ILIB therapy in knee [...] Read more.
Knee osteoarthritis (OA) is a prevalent degenerative joint disease globally, causing pain, stiffness, and disability. Intravascular laser irradiation of blood (ILIB) has been used for chronic pain and musculoskeletal disease. However, evidence on the clinical benefits and serum biomarkers post-ILIB therapy in knee OA is insufficient. We designed a double-blind randomized controlled trial to evaluate the clinical and biological outcomes of ILIB therapy for knee OA. Seventeen patients with knee OA were randomly assigned to the ILIB and control groups. The outcomes included the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Scale, visual analog scale, and biomarker analysis of interleukin (IL)-6, IL-13, IL-1β, epidermal growth factor, macrophage inflammatory protein-1β, and eotaxin. The measurements were performed at baseline and three days, one month, and three months post-intervention. The ILIB group showed a significant improvement in the WOMAC-pain score at one month of follow-up than the control group. IL-1β levels reduced significantly on day three, one month, and three months, and IL-13 levels reduced on day three and three months during follow-up in the ILIB group. ILIB therapy reduced knee OA pain for one month and significantly reduced serum IL-1β and IL-13 levels, suggesting potential for pain management. Full article
(This article belongs to the Special Issue Osteoarthritis Biomarkers, Diagnosis and Treatments)
Show Figures

Figure 1

Figure 1
<p>Study flow diagram.</p>
Full article ">Figure 2
<p>Biomarker assessment of ILIB and control group during follow-up time point: (<b>a</b>) IL-1β (<b>b</b>) IL-6 (<b>c</b>) IL-13 (<b>d</b>) EGF (<b>e</b>) MIP-1β (<b>f</b>) eotaxin; statistical analysis was performed using independent t-test or Mann–Whitney U test for intergroup comparisons (*: <span class="html-italic">p</span>-value &lt; 0.05); Wilcoxon singled-rank test for intra-group comparisons to the baseline (#: <span class="html-italic">p</span> value &lt; 0.05).</p>
Full article ">
Back to TopTop